Diabetes drug study reveals hidden genetic links to weight and inflammation
NCT ID NCT07120828
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at how two common diabetes drugs, dapagliflozin and empagliflozin, affect weight, cholesterol, and inflammation in 260 obese adults newly diagnosed with type 2 diabetes. Over six months, researchers measured changes in body weight, blood fats, and markers of oxidative stress, and also checked how a gene called CYP8B1 might influence these effects. The goal was to better understand the broader health benefits of these medications beyond blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epu
Erbil, Kurdistan, 44001, Iraq